Seaport Doses First Patient in Phase 2a Trial of GlyphAgo for Anxiety
SPTX sits 17% above its 52-week low of $14.85.
Summary
Seaport Therapeutics has dosed the first patient in a Phase 2a trial of GlyphAgo (SPT-320) for generalized anxiety disorder with sleep disturbance. The six-week, double-blind study in Australia will test two doses (16 mg and 32 mg) against placebo, with sleep and anxiety endpoints. Topline data are expected in early 2028. This follows positive Phase 1 driving simulation results for GlyphAllo in September and a strong cash position of $427.3 million reported in August. The company also plans a global Phase 2/3 trial starting in H1 2027, with data by end of 2028. The trial initiation marks a key clinical milestone for the lead asset in a large market with no new approved therapies in nearly two decades.
At the time of this announcement, SPTX was trading at $17.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $929.8M. The 52-week trading range was $14.85 to $28.38. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.